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ABSTRACT 
Despite increasing recognition of the efficacy, safety and cost-effectiveness of bariatric/metabolic surgery in the 
treatment of type 2 diabetes, few patients who may be appropriate candidates and may benefit from this type of 
surgery avail themselves of this treatment option. To identify conceptual and practical barriers to appropriate use of 
surgical procedures, a Policy Lab was hosted at the 3rd World Congress on Interventional Therapies for type 2 
diabetes on September 29, 2015. Twenty-six stakeholders participated in the Policy Lab, including academics, 
clinicians, policymakers, industry leaders and patient representatives. Participants were provided with a 
summary of available evidence about the cost-effectiveness of bariatric/metabolic surgery and the costs of 
increasing utilization of bariatric/metabolic surgery, using U.K. and U.S. scenarios as examples of distinct 
healthcare systems. There was widespread agreement among this group of stakeholders that bariatric/metabolic 
surgery is a legitimate and cost-effective approach to the treatment of type 2 diabetes in obese patients. Four 
“building blocks” were identified to facilitate policy changes: 1) communicating the scale of the costs and 
harms associated with rising prevalence of type 2 diabetes, 2) properly articulating the role of 
bariatric/metabolic surgery for certain population groups 3) identifying new funding sources for 
bariatric/metabolic surgery and 4) incorporating bariatric/metabolic surgery into the appropriate clinical 
pathways. Although more research is needed to identify specific clinical scenarios for prioritization of 
bariatric/metabolic surgery, the case appears to be strong enough to engage relevant policy makers and 
practitioners in a concerted discussion of how to better utilize metabolic surgical resources in good diabetes practice. 
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MAIN TEXT 
 
Introduction 
Type 2 diabetes comprises 90% of diabetes cases around the world (1). According to the most recent estimates 
by the International Diabetes Federation’s (IDF), 8.3% of adults in the world – 382 million  people – currently 
have diabetes, and the number is set to rise beyond 592 million in less than 25 years (2). The disease is a 
leading cause for myocardial infarction, stroke, blindness, kidney failure and amputations (3). Due to its costly 
complications, diabetes places a significant financial burden on national healthcare systems.  
In cases where diet, exercise, and medications have proved to be insufficient, bariatric/metabolic surgery can be 
an alternative to treat obesity and type 2 diabetes (4). In fact, many of the patients who undergo this type of 
surgery enjoy sustained remission of the disease, which is generally considered irreversible and inevitably 
progressive.  Randomized clinical trials demonstrate that bariatric/metabolic surgery can achieve better control 
of hyperglycemia and greater reduction of cardiovascular risk factors compared to conventional medical 
therapies and lifestyle interventions (5,6). However, despite increasing recognition of the efficacy, safety and 
cost-effectiveness of bariatric/metabolic surgery, there appear to be numerous potential barriers to the 
appropriate use of surgical procedures for those patients who may benefit. 
To address the challenges and opportunities that bariatric/metabolic surgery offers to diabetes care and 
research, the World Congress on Interventional Therapies for Type 2 Diabetes was set up as an international 
forum where clinicians, scientists and policy makers discuss available evidence on the use and study of 
bariatric/metabolic surgery and new device-based interventions. The third congress in this series was held in 
September 2015 in London to critically discuss the latest evidence on bariatric/metabolic surgery, including 
clinical outcomes, mechanisms of action and implications for healthcare policies (7). A specific aim of the 
congress was to identify and address potential barriers that may prevent access to surgical treatment of obesity 
and diabetes in eligible patients. 
The Policy Institute at King’s College London was invited to undertake a Policy Lab exercise during the 
congress, with the intent to bring together clinicians, academics, senior policy officials and patient 
representatives. The specific goals of the Policy Lab included the following: 1) to provide the latest evidence on 
cost-effectiveness of bariatric/metabolic surgery as a treatment option for obesity and diabetes, 2) to identify 
 4 
barriers to appropriate utilization of bariatric/metabolic surgery as part of the mix of interventions to address 
the rising burden of type 2 diabetes and 3) to develop health policy initiatives that may improve access to 
surgical treatment when indicated. Policy Lab participants were provided with a summary of available evidence 
about the cost effectiveness of bariatric/metabolic surgery and the costs of increasing the proportion of patients 
who would be appropriate candidates to receive bariatric/metabolic surgery procedures. This paper is structured 
as follows.  First, we describe the ‘Policy Lab.’ . Second, we present existing evidence on the global healthcare 
costs of diabetes, the evidence on the cost-effectiveness of bariatric/metabolic surgery, and our own 
calculations of the costs and benefits of meeting potential demand for bariatric/metabolic bariatric surgery in 
England and the U.S. based on published data.  Third, we report the views expressed by participants in the 
‘Policy Lab’ and relevant policy implications which emerged. 
 
What is a Policy Lab? 
Making decisions about healthcare policies is a complex task and can require an understanding of the needs of 
the target communities, of the evidence base for a range of available interventions and an assessment of the 
attitudinal, resource and logistical contexts that can affect the implementation of such policies. We prepared a 
‘Policy Lab’ (8) in which individuals of appropriate expertise debated available scientific evidence and 
identified effective means by which such evidence can inform policy and practice. The Policy Lab brought 
together twenty-six stakeholders, including academics, clinicians, policymakers, industry leaders, and patient 
representatives, with the goal of discussing bariatric/metabolic surgery as a treatment option for type 2 diabetes 
and the potential barriers to increased access to its use in practice. (Figure 1) 
Prior to the meeting, the organizing committee and the moderators of the Policy Lab researched available 
evidence and summarized data about the current cost of diabetes for healthcare systems, clinical- and cost- 
effectiveness of bariatric/metabolic surgery for type 2 diabetes and its uptake in high-income countries. We also 
assessed the number of potentially eligible patients who currently have access to bariatric/metabolic surgery  in 
two countries, England and US, as examples of two distinct types of healthcare systems, and estimated the costs 
and benefits of increasing access to the surgery.  These data were summarized and presented to participants of 
the Policy Lab during the congress. Participants considered the case for an increased provision of 
bariatric/metabolic surgery to help address the challenge of type 2 diabetes. Specifically, they were asked to 
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identify obstacles to increasing the use of bariatric/metabolic surgery and propose actions that could help 
overcome such obstacles.  
 
The global healthcare cost of diabetes  
In 2015 the global healthcare cost of diabetes was estimated to be $673 billion or 12 percent of all global 
healthcare costs, but healthcare expenditures for diabetes vary dramatically by region and by country (2). The 
world’s richest regions, North America and Europe, account for 75 percent  of global healthcare expenditures 
for diabetes. In the U.S., mean annual healthcare expenditures per person with diabetes are $10,942 and in the 
United Kingdom, they are $4,373 (2) (and estimated to account for 10 percent of the NHS budget (9)). 
Assuming constant per capita healthcare expenditures for diabetes, the global cost of diabetes is projected to 
increase by 19% to approximately $802 billion by 2040 (2). The reasons for the increasing costs of diabetes 
include population growth, aging of the population, and increasing prevalence of diabetes.  
Economic development is associated with increased access to healthcare and increased per capita healthcare 
expenditures. In high-income countries, substantial resources are used for antihyperglycemic therapy, blood 
pressure, and lipid lowering therapies and for the treatment of diabetic complications and comorbidities. In low- 
and middle-income countries, a greater proportion of resources are used for antihyperglycemic therapy and less 
for the treatment of chronic complications and comorbidities (10). With economic development, more 
individuals receive antihyperglycemic therapy and treatment for cardiovascular risk factors, complications, and 
comorbidities. A recent global systematic review revealed that the direct costs of diabetes are closely and 
positively associated with a country’s per capita gross domestic product (GDP) such that every additional dollar 
in per capita GDP corresponds with an average increase in diabetes expenditures of approximately 4 U.S. cents 
(10). Treatment for late and expensive complications of diabetes such as end-stage renal disease (ESRD) have 
also been shown to be strongly associated with national economic wealth or GDP. In low and middle income 
countries ESRD treatment rates are negligible or extremely low. (11) Treatment rates increase progressively 
with GDP per capita, and are substantially larger in high income countries. These data suggest that with global 
economic growth, access to care and the increase in healthcare costs attributable to diabetes and its 
complications will be substantially greater than hitherto projected and will be unsustainable unless action is 
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taken to slow the epidemic of type 2 diabetes. There is an urgent need to implement interventions to delay or 
prevent the development of type 2 diabetes and to slow the progression of its complications and comorbidities.  
 
Cost effectiveness of bariatric/metabolic surgery for patients with type 2 diabetes 
For the Policy Lab, evidence was gathered from two, recent, systematic reviews which included international 
evidence on the cost-effectiveness of bariatric/metabolic surgery in people with type 2 diabetes who are also 
obese (Table 1). The reviews were commissioned by the UK’s NIHR Health Technology Assessment (HTA) 
programme (12) and the National Clinical Guidelines Centre (NCGC) and were published in 2009 and 2015. 
Across both reviews, four studies were identified which met the NCGC quality criteria (13,14,15,16) (eight 
further economic evaluations were excluded on quality or scope grounds by the NCGC). All four studies used 
probabilistic decision analytic modelling to estimate the incremental costs and benefits of bariatric/metabolic 
surgery when compared to non-surgical management in patients with type 2 diabetes in periods of up to 40 
years.  Modelled populations lived in Australia (16), the UK (13,14) and USA.(15)  
Input data on clinical effectiveness, including diabetes remission rates, typically came from published RCTs 
which had a maximum of two years follow-up. (17,18) Input data on costs came from relevant literature or 
providers of health system information, including the UK’s Health and Social Care Information Centre. Three 
of the studies concluded that bariatric/metabolic surgery had a very high likelihood (95%-100%) of being cost-
effective within any reasonable threshold of what would be considered value for money in healthcare (in a 
high-income country context). Nevertheless, there was considerable variability in the estimated incremental 
cost-effectiveness ratios (ICERs) between studies, due to differences in the modelling approach, input 
parameters and assumptions made.  The fourth study concluded bariatric/metabolic surgery dominated the non-
surgical comparator, in that it was both less costly and more effective.   
For obese patients with established diabetes, a U.S. study by Hoerger et al. (2010) reported an ICER of $13,000 
per QALY for banding surgery and $12,000 per QALY for bypass surgery (both were compared to non-surgical 
management over a lifetime). Relative to patients with established diabetes, bariatric surgery led to more life 
years and lower ICERs in patients with newly diagnosed diabetes ($11,000 for banding and $7,000 for 
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bypass).1 (15) The UK study by Picot et al. (2012) estimated an ICER of £1,634 ($2,428) per QALY for 
banding surgery in obese patients with early onset type 2 diabetes over a 20 year period.  Over a two year 
period, i.e. avoiding the need to extrapolate data beyond the follow-up period of the RCT, the ICER was 
estimated to be £20,159 ($29,954) per QALY.2. Although higher, since the cost-savings arising from resolution 
of type 2 diabetes in the surgical intervention group had yet to materialize, this was nonetheless still within the 
boundaries of cost-effectiveness thresholds (at least in the UK). (14)  
 
Costs and benefits of meeting potential demand for bariatric/metabolic surgery in England and U.S. 
We used published data on the prevalence of obesity and type 2 diabetes (see Tables 2 and 3) to estimate that 
1.3m adults with a BMI greater than 30kg/m2 in England (19-24), and 10.1m in the US (25-30), are living with 
type 2 diabetes (of these, 590,000 in England and 5.5m in the US were people with a BMI greater than 
35kg/m2). Incidence data were used to estimate that there are 120,000 additional cases of type 2 diabetes 
amongst people with BMI greater than 30kg/m2 each year in England, and 860,000 additional cases each year 
in the US (of these, 54,000 in England, and 470,000 in the US, were people with a BMI greater than 35kg/m2). 
When compared to data on the annual number of diabetic patients who are treated with metabolic surgery in 
England and the US (around 1,500 people in England, Table 2, and 41,000 in the US, Table 3), only a small 
proportion of patients who might be eligible for surgery currently receive surgery.  The number of type 2 
diabetes patients currently treated each year with bariatric surgery is equivalent to 1.2% of the estimated 
number of new cases of type 2 diabetes amongst people with BMI greater than 30kg/m2 in England, or 4.8% in 
the US.. 
We estimated the potential costs and benefits of treating more obese diabetic patients with bariatric/metabolic 
surgery using published data (Tables 2 and 3) on the costs and benefits of treatment.  We considered both obese 
people with incident diabetes who are likely to become eligible for surgery each year, as well as potential 
existing cases (i.e. people in the general population with type 2 diabetes and a BMI greater than 30kg/m2 or 35 
kg/m2 who have not previously accessed treatment).  
                                                        
1 In the study by Hoerger et al, all costs were reported in 2005 US $ 
2 In the study by Picot et al, all costs were measured in 2010 UK £ and have been converted to 2010 US $ 
using yearly average currency exchange rates:  www.irs.gov/Individuals/International-Taxpayers/Yearly-
Average-Currency-Exchange-Rates accessed 21.03.16 
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During the Policy Lab we presented a scenario in which 70% of people with type 2 diabetes and a BMI greater 
than 30kg/m2 were considered by their doctors to be eligible for treatment, and 5% of them went on to choose 
surgery. Accordingly, we estimated that the current annual number of people with type 2 diabetes treated with 
bariatric/metabolic surgery would need to increase six-fold in England (to around 9,000 per annum), and by 
more than 60 per cent in the US (to around 65,000 per annum), if the potential demand for bariatric/metabolic 
surgery (from both new and existing cases of obese-diabetics) were to be addressed over a ten year period (see 
Table 4).  In this scenario, the additional annual ‘upfront’ cost of bariatric/metabolic surgery would be £35.8m 
($52.6m) in England and $686 million in the US (in 2015 prices). Thus, despite the evidence on the cost-
effectiveness of bariatric/metabolic surgery and the large costs already associated with treating diabetes 
(described above), these ‘upfront’ costs may represent a challenge to limited healthcare budgets. Nevertheless, 
the cost-effectiveness estimates in the study by Picot et al. (2012) suggest that, in the scenario where a policy of 
increased bariatric/metabolic surgery is sustained for a ten year period, health gains would be in excess of 
50,000 QALYs in England and 580,000 QALYs in the US (with associated incremental costs, which account 
for cost savings arising from diabetes remission in treated patients, of £93.7million ($137.6m) in England and 
$8.2billion in the US (in 2015 prices)). We altered the assumptions on which these estimates are based to 
provide a range of alternative scenarios (see Table 4).  For example, should the potential demand for 
bariatric/metabolic surgery (both new existing cases of obese-diabetics) be addressed over a shorter (one- or 
five- year) period, or if more than 5 per cent of the eligible population chose surgery, then annual costs and 
capacity requirements would inevitably rise substantially further. 
 
Building blocks towards policy change 
Policy change does not follow from provision of research and evidence alone. Much work is often needed for 
evidence to reach the decision-makers (31). Often the first step is identifying the relevant policy community for 
the intended policy and practice change, whether at the national or local decision-making level. In the case of 
diabetes care, the target may include national health policy, including clinical guidelines, but also local practice 
and patient advocacy groups. Decision makers at all levels will need to consider how to find sufficient funding 
to implement change, to gain the support of key stakeholders, and, crucially, to balance expenditure on 
immediate treatment needs with investment in longer term preventative strategies. Secondly, given that 
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decisions are taken at different tiers, change requires carefully targeted interventions of appropriate scale. In our 
Policy Lab we identified four ‘building blocks’ for policy and practice change that may facilitate increased 
uptake of bariatric/metabolic surgery for type 2 diabetes: 1) communicating the scale of the costs and harms 
associated with diabetes, 2) articulating the potential role of bariatric/metabolic surgery for certain population 
groups, 3) identifying the cost-effectiveness arguments that may support expanding the use of 
bariatric/metabolic surgery and 4) changing both the available resources and processes for incorporating 
bariatric/metabolic surgery into the appropriate clinical pathways. We discuss each in turn below.  
 
1 Communicating the scale of the global diabetes challenge 
Policy change requires policymakers and practitioners to be motivated to act; this is contingent on evidence that 
changes in policy and practice will improve outcomes, reduce costs and/or or reduce harms. In the case of type 
2 diabetes there appears to be a growing awareness of the magnitude of the problem globally. However, 
participants at Policy Lab noted that there is still a need to present a more detailed breakdown of the costs of 
diabetes, including better data on the prevalence of and costs of diabetes complications (such as retinopathy, 
renal disease and neuropathy) and to improve awareness of the wider social and economic costs and harms 
associated with the disease. 
 
2. Articulating the role of bariatric/metabolic surgery for the treatment of diabetes  
Once the case for action has been made, the next stage involves articulating the specific role that 
metabolic/bariatric surgery can play in the treatment of type 2 diabetes among certain population groups. The 
guidelines of the National Institute for Clinical Excellence (NICE) in England and Wales have already 
recommended that bariatric/metabolic surgery be considered for patients with a BMI of 30Kg/m2 or above with 
recent-onset (less than ten years) type 2 diabetes. For patients with a BMI of 35 Kg/m2 or above the level or 
recommendation is stronger, suggesting that these patients should be offered expedited assessment for 
bariatric/metabolic surgery (32). These guidelines reflect NICE’s interpretation of existing clinical evidence on 
the efficacy of bariatric/metabolic surgery vs non-surgical interventions in the treatment of type 2 diabetes. In 
the US, third party payors such as CMS will reimburse for specific cases of metabolic/bariatric surgery with 
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requirements for co-payment and prior medical intervention (33) and recent recommendations also recommend 
considering surgery for BMI over 30kg/m2.(34)   
The typical arguments against surgery generally focus on the advantages of investing in prevention over 
providing a relatively costlier treatment, or employing low-cost lifestyle therapeutic approaches (e.g. diet and 
physical activity) over the more invasive and (initially) expensive surgical approach. However, while devoting 
more resources to preventetive efforts and encouraging early and lasting healthy lifestyle changes is objectively 
the most logical way to tackle the epidemic of diabetes, it is similarly obvious that prevention is no longer 
possible for individuals with already established disease and that for some of them lifestyle interventions may 
be relatively ineffective (35). It is this group that constitute the gap between those who are candidates for 
bariatric/metabolic surgery vs those that received it identified earlier. Articulating this distinction clearly will be 
important in making the case for surgery. 
 
3. Identifying the cost-effectiveness arguments for bariatric/metabolic surgery 
The third building block involves furthering the understanding of the cost-effectiveness of bariatric/metabolic 
surgery versus other interventions. With pressures on public expenditure and competing budgetary priorities, 
value-for-money is highly salient in public policy. The Policy Lab participants considered the existing evidence 
on the cost-effectiveness of bariatric/metabolic surgery to be reasonably robust, with good evidence that the 
cost per QALY gained is at least comparable (and may be lower) for bariatric/metabolic surgery than for other 
approved interventions. (14,15) However, it was recognised that the completion of longer-term studies would 
be beneficial in building a more holistic picture of the evolution of the costs of bariatric/metabolic surgery over 
time, including rates of initial diabetes remission and risk of subsequent relapse and the impact of surgery on 
existent diabetes complications. 
  
4. Changing the available resources and processes for incorporating bariatric/metabolic surgery 
These first three building blocks relate to the interactions between the academic and policy communities – the 
evidence research communities must marshal and articulate for decision-makers to catalyse policy change. 
However, structural and political barriers to change may remain and identifying these may be an important step 
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towards change. Policy Lab participants identified three sets of such barriers: those related to resources, those 
regarding understanding, and those associated with processes. 
The availability of resources may be particularly pertinent – despite recognition of bariatric/metabolic surgery’s 
demonstrated cost-effectiveness. Meeting the substantial up-front costs of greater uptake of the treatment was 
viewed as a significant barrier to expanding provision in an environment of tight healthcare budgets, 
particularly in the UK context. The potential for treatment to be concentrated in Centres of Excellence was seen 
as one way of controlling delivery costs, while participants also suggested that alternative sources of finance 
could be sought, including from the private sector, to overcome short-term resource constraints, although we 
have not sought evidence that supports these suggestions within the scope of this study. The idea that up-front 
costs are a barrier to uptake may reflect some misconceptions, identified by participants, about 
bariatric/metabolic surgery. Bariatric/metabolic surgery, it was argued, is still largely conceived as a weight-
loss intervention and; as such, it may be perceived as an extremely expensive option when compared to other 
(low-cost) weight-reduction interventions (e.g. diet and lifestyle modifications). Furthermore, 
bariatric/metabolic surgery may be mistakenly considered solely as a means to prevent future obesity-related 
complications rather than as a therapy for established disease, which is particularly true when the surgery is 
used to treat diabetes. This misconception may be a significant barrier to policy changes; in fact, expediting 
access to what is perceived to be a costly, preventive intervention might not be felt as a priority at a time of 
tight healthcare budgets. 
Increasing understanding both of the severity of challenges associated with rising prevalence of diabetes and 
the process of surgery and its outcomes among the clinical and patient communities was also seen by Policy 
Lab participants as important for increasing uptake of bariatric/metabolic surgery. While current guidelines on 
obesity treatment already recommend bariatric/metabolic surgery for certain groups of patients with type 2 
diabetes (26, 36) it is likely that very few general practitioners (primary care physicians) are aware of this 
recommendation; as a result, most diabetes care providers may not refer eligible patients to surgery. There may 
also be misconceptions among doctors about the risk of bariatric/metabolic surgery (37) and inadequate 
knowledge of the improved outcomes of modern, minimally invasive surgical techniques that have helped to 
reduce the incidence of surgical complications. Better coverage of these topics in medical education and 
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training courses for all healthcare workers could help rectify this. Improved understanding among healthcare 
workers is likely to filter down to patients suffering from type 2 diabetes.  
 
Finally, according to the participants, processes matter, including how services are commissioned, delivered 
and incentivised. Participants noted a common complaint related to the poor or patchy provision of specialist 
pre-surgery services and the lack of coordination between preparation for bariatric/metabolic surgery, surgery 
itself and follow-up care. It was suggested that the creation of multidisciplinary teams could bring coherence to 
the system and prevent bottlenecks from emerging. Bariatric/metabolic surgery also does not appear to be 
integrated into the established clinical care pathway for type 2 diabetes in England- for example, while 
bariatric/metabolic surgery is a recommended option for treating diabetes in the clinical pathway for obesity 
treatment, there is no reference to bariatric/metabolic surgery in either the previous or recently updated NICE 
guidelines on the management of type 2 diabetes. (38) Including bariatric/metabolic surgery in diabetes 
treatment algorithms may help increase its visibility for relevant clinicians and improve access to surgery for 
eligible patients who opt for this surgery. This was the aim of the 2nd Diabetes Surgery Summit (DSS-II), 
which was held in conjunction with the 3rd world congress on interventional therapies for type 2 diabetes in 
September 2015 (report to be published in Diabetes Care).  
 
Reframing the concept of bariatric/metabolic surgery 
The Policy Lab hosted at the 3rd World Congress on Interventional Therapies for type 2 diabetes provided 
evidence of agreement among stakeholders that bariatric/metabolic surgery is an appropriate and cost-effective 
approach to the treatment of type 2 diabetes in some groups of patients. Given the evidence and challenges, 
participants identified four ‘building blocks’ to facilitate changes in policy and practice and adequately increase 
appropriate uptake of bariatric/metabolic surgery for the treatment of diabetes: 1. communicating the scale of 
the costs and harms associated with rising rates of type 2 diabetes, 2. articulating the role of metabolic/bariatric 
surgery for certain populations 3. identifying where/how resources might be found to fund bariatric/metabolic 
surgery and 4. changing the available resources and processes for incorporating bariatric/metabolic surgery into 
the appropriate clinical pathways.  
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One further issue that arose in discussions in the Policy Lab was that the name of “bariatric” may negatively 
influence people’s understanding of the role of surgery in diabetes and its potential benefits. In fact, surgery is 
generally viewed by many as a risky and worrying undertaking, to be avoided if at all possible. Conceiving 
surgery solely as a weight-loss intervention, as implied in the name “bariatric”, may be viewed as extremely 
risky compared to alternative, conservative weight loss interventions (diet and lifestyle modifications). Placing 
these concerns alongside the potential burden of inadequately controlled type 2 diabetes may be helpful on this 
point. Further, obesity itself carries many connotations that may affect clinicians and others’ inclination to 
recommend it. In fact, surgery could be seen as a drastic step to address a challenge that many consider 
avoidable through self-control and weight loss. This issue may be addressed by properly using terms such as 
“metabolic” or “diabetes” surgery when gastrointestinal operations are offered with the primary intent to treat 
fully developed type 2 diabetes. We also noted above the importance of including bariatric/metabolic surgery in 
clinical guidelines for diabetes care as opposed to just in guidelines for obesity treatment.  
 
Conclusions 
This paper has provided new calculations on the proportion of potentially eligible obese-diabetics who 
currently receive metabolic/bariatric surgery in light of new guidelines which recommend considering surgery 
for diabetic patients with a BMI over 30kg/m2.(34)  This updates previous estimates provided by the American 
Society for Metabolic and Bariatric Surgery (35).  Although more research is needed to identify specific clinical 
scenarios for prioritization of surgical treatment in patients with type 2 diabetes, the case appears to be strong 
enough to engage relevant policy makers and practitioners in a concerted discussion of how to extend 
appropriate use of bariatric/metabolic surgery as part of the of the mix of approaches to address the growing 
burden of type 2 diabetes. 
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Figures 
Figure 1. Distribution of participant roles at the Policy Lab 
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Figure 2. Flow chart to demonstrate how estimates for cost model were calculated (England example) 
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Figure 3. Building blocks of policy change for appropriate utilization of surgery in treatment of type 2 diabetes 
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Tables 
Table 1: Evidence from two studies on the cost-effectiveness of bariatric/metabolic surgery in patients with 
type 2 diabetes 
 England [14] US [15] 
INTERVENTION 
Description Laparoscopic adjustable gastric banding surgery Gastric bypass surgery 
Upfront cost £4,5463 ($6,754) $23,871 (all costs were measured in 2005 US $) 
Total lifetime 
cost 
£35,055 ($52,088)  (including surgery, consumables, 
inpatient stay, dietitian, therapy, re-operations) (20 years) 
$99,944 (including follow-up care visits, long-term 
complications, revisional surgery, diabetic related 
medicine) 
Total lifetime 
QALYs 
11.49 (20 years) 9.38 
COMPARATOR 
Description Non-surgical weight loss programme (including low 
calorie diet for 6 months) 
Standard care for type 2 diabetes 
Total lifetime 
cost 
£33,262 ($49,423) (including regular contact with 
physician, parmacotherapy, Optifast, Orlistat) (20 years) 
$79,618 (including diabetic related medicine) 
Total lifetime 
QALYs  
10.39 (20 years) 7.68 
COST-EFFECTIVENESS 
ICER £1,634 ($2,428) per QALY gained* 
Probability that intervention is cost-effective at £30,000 
($44,577)/QALY threshold = 100% 
$12,000 per QALY gained 
Probability that intervention is cost-effective at 
$30,000/QALY threshold = 95% 
 Notes: 
*Resolution of type 2 diabetes in the intervention group (compared to non-intervention group) made the greatest 
contribution to the reduction in the ICER from £20,159 ($29,954)  at 2 years (i.e. without extrapolation of RCT 
data) to £1,634 ($2,428) at 20 years [15] 
1 ICER: incremental cost effectiveness ratio 
2 QALY: quality adjusted life year 
                                                        
3 In the study by Picot et al, all costs were measured in 2010 UK £ and have been converted to 2010 US $ 
using yearly average currency exchange rates:  www.irs.gov/Individuals/International-Taxpayers/Yearly-
Average-Currency-Exchange-Rates accessed 21.03.16 
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Table 2:  Published estimates of the prevalence and incidence of type 2 diabetes and obesity, and cost and 
benefits of bariatric surgery (England) 
 
Variable Value Source/justification   
Population prevalence and incidence 
Prevalence of type 2 
diabetes in adult 
population 
5.6% 6.2% (doctor diagnosed, i.e. 
excluding undiagnosed, type 1 and 
type 2 diabetes) [20], of which 90% 
is type 2 diabetes [9] 
  
Incidence of diabetes  515 
/100,000 
/year 
[21]   
Proportion of type 2 
diabetics with BMI>35  
23.6% 
 
National Diabetes Audit 2012/13 [22]   
Proportion of type 2 
diabetics with 
30>BMI>35 
28.9%   
Assumptions about appropriate utilisation of bariatric surgery 
Proportion suitable for 
surgery 
70% Based on National Diabetes Audit 
2012/13 which says 70% of obese 
diabetics receive “usual care” / tier 3 
intervention [22] 
  
Proportion who choose 
surgery 
5% Expert opinion   
Age range of adults 
who are suitable for 
surgery 
All ages 
over 18 
years 
Expert opinion   
Published estimates of current utilisation 
Numbers treated 6,170 Estimates provided by the National 
Bariatric Surgery Registry based on 
2012/13 HES data (we assumed this 
referred only to England). [23] 
We multiplied data on 11 months 
(n=5,656) by 12/11. 
Another study also provided a similar 
estimate. [24] 
 
  
Proportion of those 
patients treated who 
have type 2 diabetes 
24% 1.1 [24]   
Published estimates of costs and benefits of surgery 
“Upfront” cost £4,892 
($7.184) 
Laparoscopic adjustable banding.  
Adjusted for 2015 prices using 
£4,546 in 2010.[14] 
  
Incremental 
costs 
 £1,928 
($2,831) 
Laparoscopic adjustable banding 
20 year incremental costs and 
QALYs for patients with type 2 
diabetes (£1,792 in 2010) 
(LGBP or other surgery not 
available) 
Estimates are for 30>BMI<40 
  
Incremental 
QALYs 
 1.10 
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Table 3:  Published estimates of the prevalence and incidence of type 2 diabetes and obesity, and cost and 
benefits of bariatric/metabolic surgery (US) 
 
Variable Value Source/justification   
Population prevalence and incidence 
Prevalence of type 2 
diabetes in adult 
population 
8.1% 
 
National Health Interview Survey 
2014:  9.0% (type 1 and type 2) [25], 
of which we assumed 90% is type 2 
diabetes [9] 
 
  
Incidence of diabetes  690 
/100,000 
/year 
National Health Interview Survey 
2014 [26] 
  
Proportion of type 2 
diabetics with BMI>35  
27.7% NHANES data [ref]   
Proportion of type 2 
diabetics with 
30>BMI>35 
23.2%   
Assumptions about appropriate utilisation of bariatric surgery 
Proportion suitable for 
surgery 
70% Based on estimates for England 
described in Table 2 
  
Proportion who choose 
surgery 
5% Expert opinion   
Age range of adults 
who are suitable for 
surgery 
All ages 
over 18 
years 
Expert opinion   
Published estimates of current utilisation 
Numbers treated 124,838 2008. Excludes outpatient 
procedures. [27] 
 
  
Proportion of those 
patients treated who 
have type 2 diabetes 
33% 1.2 [27]   
Published estimates of costs and benefits of surgery 
“Upfront” cost $28,161 Bypass surgery (includes all first year 
costs)  
Adjusted for 2015 prices using 
$23,871 in 2005 [ref.] 
  
Incremental costs of 
treatment  
$23,979 Bypass surgery  
Adjusted for 2015 prices using 
$20,326 in 2005 [ref.] 
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Incremental QALYs 1.70 Bypass surgery [ref.] 
Figures relate to people with 
established type 2 diabetes and 
BMI>35 (thus a conservative estimate 
of QALY gains compared to newly 
diagnosed diabetics) 
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Table 4:  Estimates of costs and benefits of meeting appropriate utilization for bariatric/metabolic surgery in 
England and the US 
 
 England US 
Scenario:   
Proportion choosing surgery 
1%  5%  
(base case) 
20% 1%  5%  
(base case) 
20% 
Additional upfront annual cost 
of clearing the ‘backlog’ in 1 
year 
£41.7m 
($61.2m) 
£237.7m 
($349.0m) 
£972.4m 
($1.4bn) 
$1.3bn $9.7bn $42.1bn 
Lifetime incremental cost of 
clearing the backlog 
£16.4m 
($24.1m) 
£93.7m 
($137.6m) 
£383.2m 
($562.7m) 
$854m $8.2bn $35.9bn 
Lifetime incremental QALYs of 
clearing the backlog 
9,385 53,442 218,655 60,554 582,907 2.5m 
Time taken to treat existing 
obese diabetics in the population 
(i.e. the ‘backlog’) if no change 
in uptake of surgery 
14 years Never* Never* 2 years 32 years Never* 
Additional annual 
surgery needed to 
clear the ‘backlog’ 
within 1, 5 and 10 
years 
1 year 8,532 48,584 198,777 35,620 342,887 1.5m 
5 year 1,196 11,905 52,063 0 59,740 362,550 
10 years 279 7,320 33,724 0 24,347 220,976 
 
*never since the number of new cases presented each year exceeds the number currently treated 
 
All monetary values in this table were measured in 2015 UK £ or 2015 US $.  2015 UK £s have been converted to 
2015 US $ using using yearly average currency exchange rates:  www.irs.gov/Individuals/International-
Taxpayers/Yearly-Average-Currency-Exchange-Rates accessed 21.03.16 
 
